Nextcure, Inc last reported quarterly results on Aug 6, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$2.80. It usually reports 23–37 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 4, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 5, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 23–37 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-15
+44.4%
|
-2.80
+75.2%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-10
+10.8%
|
-1.87
+60.2%
|
|
Jan 23, 2026
23 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-9
+18.7%
|
-2.38
+52.1%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-9
+25.3%
|
-3.22
+34.9%
|
|
Aug 7, 2025
38 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-27
-74.0%
|
-11.29
-70.8%
|
|
May 1, 2025
31 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-11
+35.8%
|
-4.70
-670.5%
|
|
Mar 6, 2025
65 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-12
+19.8%
|
-4.97
-858.8%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-12
+19.3%
|
-4.95
-870.6%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NXTC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Baltimore, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1661059
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.